If you or a loved one is taking Reglan and notices unusual, uncontrollable movements of the face, tongue, or limbs, these could be early signs of tardive dyskinesia. This condition can persist even after stopping the medication. Building on decades of pharmacovigilance research, this page outlines the specific symptoms to watch for and the clinical steps to take if they appear.
Tardive dyskinesia (TD) is a serious movement disorder characterized by potentially irreversible, involuntary movements of the face, tongue, trunk, and extremities. The condition is clinically diagnosed based on the presence of these abnormal movements, which can be disfiguring and may persist even after the causative medication is discontinued. The clinical presentation often includes repetitive, purposeless motions such as lip smacking, grimacing, or rapid eye blinking, and can extend to choreiform movements of the limbs or trunk. Diagnosis is primarily clinical, relying on a thorough history of medication exposure and physical examination, as there are no definitive laboratory tests for TD. Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis. According to the FDA-approved labeling, Reglan is indicated for treatment of GERD for 4 to 12 weeks in adults who fail conventional therapy, and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling explicitly states that Reglan has not been shown to be safe or effective for GERD beyond 12 weeks, and it is not recommended for pediatric use due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the striatum is believed to lead to upregulation of these receptors, resulting in an imbalance between dopamine and acetylcholine signaling. This imbalance can produce the involuntary movements characteristic of TD. The risk of developing TD increases with longer duration of treatment and higher total cumulative dosage of metoclopramide (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA boxed warning emphasizes that Reglan can cause TD, which may be irreversible, and that the risk is dose- and duration-dependent (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Adequacy of warnings regarding Reglan and TD is a critical risk consideration. The FDA requires a boxed warning on Reglan labeling, which states that metoclopramide can cause TD, that the risk increases with treatment duration and cumulative dose, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also advises using Reglan for the shortest duration necessary and reassessing the need for continued treatment periodically. For patients with diabetic gastroparesis, the labeling recommends avoiding treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring or informed consent regarding TD risk. This gap between regulatory warnings and clinical practice has been a central issue in litigation.
Settlement-related considerations for affected patients in Virginia involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Virginia, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries like TD, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, the timeline between exposure to Reglan and documented harm can be variable. TD may develop after months or years of metoclopramide use, and symptoms can emerge gradually, making the date of discovery complex. Patients may not immediately recognize the connection between their involuntary movements and Reglan use, especially if they were not adequately warned. The statute of limitations clock typically starts when the patient knows or has reason to know of both the injury and its cause. Given that TD can be irreversible and may progress even after discontinuation of Reglan, early recognition is crucial. Patients who develop TD after prolonged Reglan use should consult legal counsel promptly to assess their claim within Virginia's statutory time limits.
In summary, Reglan-induced TD is a well-documented adverse effect with a clear mechanistic basis and FDA-mandated warnings. The risk is dose- and duration-dependent, and the labeling explicitly limits use to 12 weeks for GERD and advises caution for longer use in gastroparesis. For Virginia patients, the statute of limitations for filing a TD-related claim is two years from discovery of the injury, making timely legal evaluation essential. Settlement considerations often hinge on the adequacy of warnings provided to the patient and the duration of Reglan exposure relative to labeling recommendations. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397)
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Virginia, the statute of limitations for personal injury claims, including those for tardive dyskinesia caused by Reglan, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means affected individuals must file a lawsuit within two years of recognizing their symptoms and linking them to Reglan use.
Reglan (metoclopramide) is a dopamine receptor antagonist. Chronic blockade of dopamine D2 receptors in the brain's striatum can lead to upregulation of these receptors, causing an imbalance between dopamine and acetylcholine signaling. This imbalance results in the involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.